AYTU BioPharma
AYTU
8 hedge funds and large institutions have $325K invested in AYTU BioPharma in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 9 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
43% less funds holding
Funds holding: 14 → 8 (-6)
58% less capital invested
Capital invested by funds: $765K → $325K (-$440K)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$76.8K |
| 2 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$61.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$26.8K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$25K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$926 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$95K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$81K |
| 3 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$53K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$46.3K |
| 5 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$39K |
AYTU Hedge Fund Activity: Q3 2018 in Review
8 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2018, worth a combined $325K — down 58% from $765K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AYTU and 3 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $76.8K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $95K sold.
- 8 institutional investors held AYTU BioPharma (AYTU) as of Q3 2018, down from 14 in Q2 2018.
- Funds reported $325K of AYTU BioPharma stock for Q3 2018, down 58% quarter-over-quarter.
- 3 funds opened new AYTU BioPharma positions in Q3 2018 and 9 closed out, a net change of -6 holders.
- The largest AYTU BioPharma buyer in Q3 2018 was Renaissance Technologies, an estimated $76.8K added.
- The largest AYTU BioPharma seller in Q3 2018 was Susquehanna International Group, an estimated $95K sold.
Based on aggregated 13F filings for Q3 2018.